Thu, 5 Nov
Rubicon Research
Q2 revenue rose 40% to ₹576 Cr with 25% operating EBITDA margin and ₹90 Cr PAT. Arena acquisition flatters growth, and recent plant inspections remain unresolved.
Summary ready
Earnings calls
Rubicon Research concalls
Every Rubicon Research earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Q2 revenue rose 40% to ₹576 Cr with 25% operating EBITDA margin and ₹90 Cr PAT. Arena acquisition flatters growth, and recent plant inspections remain unresolved.
Outlook
Guides FY27 operating EBITDA margin 24%+ (from 23%+); ₹313 Cr of ₹500 Cr R&D spent, rest expected in three quarters.
Earlier call summaries
All →
21:58 IST
NSE
Earnings Call
Rubicon Research Earnings Call Transcript: Key Takeaways
Rubicon Research delivers stellar Q1FY27 results with a 51% revenue jump and 100%+ PAT growth, largely fueled by strong US specialty sales and successful inorganic integration.
18:42 IST
BSE
Earnings Call
Rubicon Research Earnings Call: Key Takeaways
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.
12:01 IST
NSE
Earnings Call
Rubicon Research Earnings Call: Key Takeaways
Rubicon Research delivered a strong Q4 FY26 with 44% revenue growth and 112% profit increase, driven by a robust product pipeline and stable pricing despite outsourcing manufacturing for excess demand.
17:25 IST
BSE
Earnings Call
Rubicon Research Earnings Call: Key Takeaways
Rubicon Research (Q4 FY26) reported revenue of ₹5,139M (up 43.5% YoY) and PAT of ₹768M (up 111.8% YoY). Strategy focuses on specialty products and US nasal spray market leadership.
Rubicon Research Limited: key numbers
- Share price
- ₹1,659.30
- Market cap
- ₹27,467 Cr
- Revenue (annual)
- ₹1,754 Cr
- Net profit (annual)
- ₹246.7 Cr
- P/E (TTM)
- 84.5×Sector 43.0×
- Promoter holding
- 51.25%-8.51% QoQ
- FII holding
- 9.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.